Related Experiment Video
Updated: Jun 24, 2026

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
Published on: February 10, 2013
Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists
Jacob Abraham1, James O Mudd, Navin K Kapur
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Insights
Intravenous catecholamines and beta-receptor agonists can trigger stress cardiomyopathy, a condition of reversible heart dysfunction. This study highlights the role of excessive sympathetic stimulation in this cardiac syndrome.
Area of Science:
- Cardiology
- Pharmacology
- Critical Care Medicine
Background:
- Stress cardiomyopathy, a transient cardiac dysfunction, is linked to intense stress and sympathetic overstimulation.
- The direct causal link between sympathetic stimulation and stress cardiomyopathy remains unclear.
Purpose of the Study:
- To investigate stress cardiomyopathy precipitated by intravenous catecholamines and beta-receptor agonists.
- To establish a causal link between sympathetic stimulation and stress cardiomyopathy.
Main Methods:
- Observational study of 9 patients who developed stress cardiomyopathy after epinephrine or dobutamine administration.
- Evaluation included coronary angiography, echocardiography, electrocardiography, and cardiac enzymes.
Main Results:
- All patients showed QTc interval prolongation and elevated troponin-I without obstructive coronary disease.
- Left ventricular dysfunction, including various "ballooning" patterns, was observed with a median ejection fraction of 35% on admission.
- Complete recovery of left ventricular systolic function was noted within a median of 7 days.
Conclusions:
- Catecholamines and beta-receptor agonists can precipitate stress cardiomyopathy, mimicking its key features.
- These findings strongly suggest excessive sympathetic stimulation is central to the pathogenesis of stress cardiomyopathy.
Objectives:
The aim of this study was to report a series of patients with stress cardiomyopathy precipitated by the intravenous administration of catecholamines and beta-receptor agonists.
Background:
Stress cardiomyopathy is a syndrome of transient cardiac dysfunction precipitated by intense emotional or physical stress. Excessive sympathetic stimulation is believed to be central to the pathogenesis of this disorder, but a causal link has not been convincingly demonstrated.
Methods:
We observed 9 cases of stress cardiomyopathy precipitated immediately by the intravenous administration of epinephrine (n = 6) or dobutamine (n = 3). Patients were evaluated with coronary angiography and with serial echocardiography, electrocardiography, and cardiac enzymes.
Results:
The median age was 44 years (interquartile range [IQR]: 30 to 48 years), and 7 (78%) were woman. Troponin-I was mildly elevated (median 4.07 ng/ml, IQR: 0.47 to 5.63 ng/ml), but none of the patients undergoing angiography had obstructive coronary disease. All patients developed corrected QT interval (QTc interval) prolongation (median QTc interval 504 ms, IQR: 477 to 568 ms) within 24 h of receiving drug. All 3 previously described variants of left ventricular "ballooning" (apical, midventricular, and basal) were observed. The median ejection fraction on admission was 35% (IQR: 35% to 40%). During follow-up (median 7 days, IQR: 4 to 13 days) there was recovery of left ventricular systolic function in all patients (median ejection fraction 55%, IQR: 40% to 60%, p < 0.001 vs. admission).
Conclusions:
Exposure to catecholamines and beta-receptor agonists used routinely during procedures and diagnostic tests can precipitate all the features of stress cardiomyopathy, including cardiac isoenzyme elevation, QTc interval prolongation, and rapidly reversible cardiac dysfunction. These observations strongly implicate excessive sympathetic stimulation as central to the pathogenesis of this unique syndrome.
Related Concept Videos
Heart Failure Drugs: β-Blockers
Heart Failure II: Pathophysiology
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure Drugs: Inotropic Agents
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Cardiomyopathy III: Hypertrophic Cardiomyopathy
